Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with ...
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
FreshBaked! on MSN4d
What was there BEFORE the MATTERHORN | Disneyland HistoryDiscover the fascinating history of Disneyland's Matterhorn and what once existed in its place. Uncover the stories and ...
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...
The Monterey County Herald on MSN4d
Travel: Skiing the Swiss Alps is like traversing the roof of the worldExplore Switzerland’s Zermatt, as well as Chamonix in France, for thrills on the slopes and mind-blowing scenery.
Victory Ventures, in collaboration with Matterhorn Venture Partners, proudly announces the acquisition of a 22,500 ...
The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...
AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...
Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...
The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback